Vascular endothelial growth factor genotypes, haplotypes, gender, and the risk of non-small cell lung cancer

Clinical Cancer Research

Volumn 14, Issue 2, 2008, Pages 612-616

  Zhai, Rihong ^a   Liu, Geoffrey ^a   Zhou, Wei ^a   Su, Li ^a   Heist, Rebecca Suk ^a   Lynch, Thomas J ^a   Wain, John C ^b   Asomaning, Kofi ^a   Lin, Xihong ^b   Christiani, David C ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN;

ARTICLE; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENDER; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HAPLOTYPE; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

AGED; ALLELES; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; POLYMORPHISM, GENETIC; RISK FACTORS; SEX CHARACTERISTICS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 38949126951     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1655     Document Type: Article

References (40)

1. Voelkel NF, Vandivier RW, Tuder RM. Vascular endothelial growth factor in the lung. Am J Physiol Lung Cell Mol Physiol 2006;290:L209-21.
2. D'Amico TA. Angiogenesis in non-small cell lung cancer. Semin Thorac Cardiovasc Surg 2004;16:13-8.
3. Macchiarini P, Fontanini G, Hardin MJ, Squartini F, Angeletti CA. Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet 1992;340:145-6.
4. Yuan A, Yang PC, Yu CJ, et al. Tumor angiogenesis correlates with histologic type and metastasis in non-small-cell lung cancer. Am J Respir Crit Care Med 1995;152:2157-62.
5. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005;69 Suppl 3:4-10.
6. Fontanini G, Boldrini L, Chine S, et al. Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomas. Br J Cancer 1999;79:363-9.
7. Yuan A, Yu CJ, Chen WJ, et al. Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small cell lung cancer. Int J Cancer 2000;89:475-83.
8. Han H, Silverman JF, Santucci TS, et al. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol 2001;8:72-9.
9. Joseph IB, Nelson JB, Denmeade SR, Isaacs JT. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res 1997;3:2507-11.
10. Kaya A, Ciledag A, Gulbay BE, et al. The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients. Respir Med 2004;98:632-6.
11. Dudek AZ, Mahaseth H. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Cancer Invest 2005;23:193-200.
12. Shimanuki Y, Takahashi K, Cui R, et al. Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer. Lung 2005;183:29-42.
13. Yano S, Matsumori Y, Ikuta K, Ogino H, Doljinsuren T, Sone S. Current status and perspective of angiogenesis and antivascular therapeutic strategy: non-small cell lung cancer. Int J Clin Oncol 2006;11:73-81.
14. Koukourakis MI, Papazoglou D, Giatromanolaki A, et al. VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 2004;46:293-8.
15. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 2000;12:1232-5.
16. Stevens A, Soden J, Brenchley PE, et al. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 2003;63:812-6.
17. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 2000;37:443-8.
18. Jin Q, Hemminki K, Enquist K, et al. Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res 2005;11:3647-53.
19. Sfar S, Hassen E, Saad H, Mosbah F, Chouchane L. Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome. Cytokine 2006;35:21-8.
20. Krippl P, Langsenlehner U, Renner W, et al. A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer 2003;106:468-71.
21. Kataoka N, Cai Q, Wen W, et al. Population-based case-control study of VEGF gene polymorphisms and breast cancer risk among Chinese women. Cancer Epidemiol Biomarkers Prev 2006;15:1148-52.
22. Lee SJ, Lee SY, Jeon HS, et al. Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev 2005;14:571-5.
23. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004;96:434-42.
24. Su L, Zhou W, Asomaning K, et al. Genotypes and haplotypes of matrix metalloproteinase 1, 3 and 12 genes and the risk of lung cancer. Carcinogenesis 2006;27:1024-9.
25. Kraft P, Cox DG, Paynter RA, et al. Accounting for haplotype uncertainty in matched association studies: a comparison of simple and flexible techniques. Genet Epidemiol 2005;28:261-72.
26. Zhai R, Gong MN, Zhou W, et al. Genotypes and haplotypes of VEGF gene are associated with higher ARDS mortality and lower VEGF plasma levels. Thorax 2007;62:718-22.
27. Zhou W, Liu G, Park S, et al. Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer. Cancer Epidemiol Biomarkers Prev 2005;14:491-6.
28. Awata T, Inoue K, Kurihara S, et al. A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 2002;51:1635-9.
29. Awata T, Kurihara S, Takata N, et al. Functional VEGF C-634G polymorphism is associated with development of diabetic macular edema and correlated with macular retinal thickness in type 2 diabetes. Biochem Biophys Res Commun 2005;333:679-85.
30. Petrovic D, Verhovec R, Globocnik M, Osredkar J, Peterlin B. Association of vascular endothelial growth factor gene polymorphism with myocardial infarction in patients with type 2 diabetes. Cardiology 2007;107:291-5.
31. Twombly R. New studies fan controversy over gender risk in lung cancer. J Natl Cancer Inst 2004;96:898-900.
32. Caracta CF. Gender differences in pulmonary disease. Mt Sinai J Med 2003;70:215-24.
33. Olak J, Colson Y. Gender differences in lung cancer: have we really come a long way, baby? J Thorac Cardiovasc Surg 2004;128:346-51.
34. Sordello S, Bertrand N, Plouët J. Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens. Biochem Biophys Res Commun 1998;251:287-90.
35. Stewart RJ, Panigrahy D, Flynn E, Folkman J. Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol 2001;165:688-93.
36. Sibug RM, Helmerhorst FM, Tijssen AM, de Kloet ER, de Koning J. Estrogen reduces vascular endothelial growth factor (164) expression in the mouse nucleus paraventricularis of the hypothalamus. Neurosci Lett 2002;333:199-202.
37. Niklaus AL, Babischkin JS, Aberdeen GW, Pepe GJ, Albrecht ED. Expression of vascular endothelial growth/permeability factor by endometrial glandular epithelial and stromal cells in baboons during the menstrual cycle and after ovariectomy. Endocrinology 2002;143:4007-17.
38. Joseph IB, Isaacs JT. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. Cancer Res 1997;57:1054-7.
39. Arinaga M, Noguchi T, Takeno S, Chujo M, Miura T, Uchida Y. Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with non small cell lung carcinoma. Cancer 2003;97:457-64.
40. Juczewska M, Chyczewski L, Telego M, et al. Studies on angiogenesis intensity in lung cancer in aspect of its correlation with histological type of tumor and clinical stage. Rocz Akad Med Bialymst 1997;42:254-70.